- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Indacaterol intermediate 312753-53-0
【Catalogue Number】AP4507
【CAS #】 312753-53-0
【Molecular formula】 C13H20ClN
[Product Introduction] 5,6-diethyl-2,3-dihydro-1H-indene-2-amine hydrochloride, English name is 5,6-Diethyl-2,3-dihydro-1H-inden-2 -amine hydrochloride, American Chemical Abstracts Registry number is cas 312753-53-0.
Indacaterol intermediate
5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride
CAS 312753-53-0
Alias Indate maleate intermediate
Catalog number AP4507
CAS # 312753-53-0
Molecular formula C13H20ClN
Molecular weight 225.76
Structural formula
Product introduction
CAS 312753-53-0 5,6-diethyl-2,3-dihydro-1H-indene-2-amine hydrochloride, English name 5,6-Diethyl-2,3-dihydro-1H-
inden-2-amine hydrochloride, American Chemical Abstracts Registry Number cas 312753-53-0.
5,6-Diethyl-2,3-dihydro-1H-indene-2-amine hydrochloride (cas 312753-53-0) is an intermediate of indate maleate. Indate maleate is a bronchodilator, belongs to the class of long-acting inhaled β2 receptor agonists (LABA), and is suitable for maintenance treatment of adult patients with chronic obstructive pulmonary disease. Indacaterol has a 5 minute onset and lasts 24 hours. This product is produced by Novartis Pharmaceuticals, Switzerland, and has been marketed in more than 70 countries and regions around the world since 2009; it was approved for listing in China by the State Drug Administration in June 2012 under the trade name Onbrez®.
VIWIT 沪ICP备12014533号-1
